Adamas Pharmaceuticals, Inc. (ADMS)
| Market Cap | 231.13M |
| Revenue (ttm) | 79.29M |
| Net Income (ttm) | -53.33M |
| Shares Out | 35.17M |
| EPS (ttm) | -1.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $5.09 |
| Previous Close | $5.15 |
| Change ($) | -0.06 |
| Change (%) | -1.17% |
| Day's Open | 5.15 |
| Day's Range | 5.08 - 5.32 |
| Day's Volume | 226,466 |
| 52-Week Range | 2.43 - 9.15 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees restricted...
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. ...
TUCSON, Ariz. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to de...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Pharmaceuticals Inc (NASDAQ: ADMS) has announced the publication of pooled analyses of Gocovri (amantadine) from pivotal studies in Parkinson's disease. Data were published in the peer-reviewed j...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees restricted ...
Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas (ADMS) delivered earnings and revenue surprises of -20.76% and 1.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which m...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
Adamas Pharmaceuticals (NASDAQ:ADMS) announces its next round of earnings this Tuesday, February 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affect...
-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71...
EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...
Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...
EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new empl...
Amended terms will provide added flexibility to help drive the growth of the Company Amended terms will provide added flexibility to help drive the growth of the Company
As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® As part of this agreement Adamas will acquire the global rights to OSMOLEX ER®
EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...
EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people a...
EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...
EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new em...
Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhy...
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript
Adamas (ADMS) delivered earnings and revenue surprises of 16.00% and -5.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019
EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people ...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020
EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November ...
EMERYVILLE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people a...
EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to peopl...
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to peop...
EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to peopl...
Adamas Pharmaceuticals recently reported their Q2 earnings with a strong beat on EPS and revenue. The market responded appropriately with the stock nearly doubling in subsequent trading days.
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q2 2020 Results - Earnings Call Transcript
About ADMS
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Apr 10, 2014 |
| CEO Neil McFarlane | Employees 138 |
| Stock Exchange NASDAQ | Ticker Symbol ADMS |
Financial Performance
In 2020, ADMS's revenue was $74.46 million, an increase of 36.28% compared to the previous year's $54.64 million. Losses were -$57.40 million, -45.43% less than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for ADMS stock is "Buy." The 12-month stock price forecast is 8.79, which is an increase of 72.69% from the latest price.